Dr. Homan returned to the rigorous demands of leading a start-up therapeutics company and co-founded MetasTx, LLC with Drs. Somanath Shenoy and Brian Cummings because he was so impressed with the published results from their academic research and strongly believes they have identified a potential breakthrough drug that may significantly improve the armamentarium for treating metastatic cancer to greatly extend and improve patients' lives. Since formation in August 2021, MetasTx has made great progress and is poised to begin IND-enabling studies that will lead to the critical First-In-Human clinical studies. Dr. Homan has drawn upon his academic background in pharmacology, as well as hands-on and senior leadership experience in a broad range of patient focused therapeutic categories in start-up and multi-billion dollar healthcare companies to build an extensive global network that he can call upon as needs arise. As Founder and CEO of biotech and medical device companies in USA and UK he has achieved successful marketing authorization, commercialization and exits, and has had extensive experience transitioning technology from academic labs to businesses, including recent projects in neurodegenerative and psychiatric diseases. For Sterling Health and The Boots Company (BHI), he led growth of businesses in consumer-focused pharmaceuticals and has led commercialization of hundreds of successful products. At Sterling, he rapidly progressed through clinical science, marketing and sales to lead R&D, regulatory and clinical affairs for Europe, led global Analgesic, GI, and Skin Care portfolios and instituted innovative product development organizations and processes. Dr. Homan led all scientific, medical, regulatory and development functions for start-up BHI with teams in the UK, France, Germany, Australia, and Thailand. He was responsible for integration of all scientific, medical and regulatory functions for two major acquisitions, and development of partnerships in Europe, U.S., India and Japan that built BHI to £500 million revenue and resulted in a £2 billion sale to Reckitt Benckiser in 2005. As Head of Corporate Development and Innovation for Boots plc, he led institution of best practices internationally, and coached Directors in value creation through innovation. He has served as a Director for Whitehorse Recovery Center, NH, and is a member of the Steering Committee for CUMC TRx Accelerator, as well as a successful angel inveator. Dr. Homan has a PhD in Pharmacology from UGA and a MBA from NYU Stern.